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Gregory Hess1,2*, Arie Barlev3, Karen Chung3, Jerrold W Hill1 and Eileen Fonseca1Abstract
Background: To estimate the costs (paid amounts) of palliative radiation episodes of care (REOCs) to the bone for
patients with bone metastases secondary to breast or prostate cancer.
Methods: Claims-linked medical records from patients at 98 cancer treatment centers in 16 US states were
analyzed. Inclusion criteria included a primary neoplasm of breast or prostate cancer with a secondary neoplasm of
bone metastases; ≥2 visits to ≥1 radiation center during the study period (1 July 2008 through 31 December 2009)
on or after the metastatic cancer diagnosis date; radiation therapy to ≥1 bone site; and ≥1 complete REOC as
evidenced by a >30-day gap pre- and post-radiation therapy.
Results: The total number of REOCs was 220 for 207 breast cancer patients and 233 for 213 prostate cancer
patients. In the main analysis (which excluded records with unpopulated costs) the median number of fractions per
a REOC for treatment of metastases was 10. Mean total radiation costs (i.e., radiation direct cost + cost of
radiation-related procedures and visits) per REOC were $7457 for patients with breast cancer and $7553 for patients
with prostate cancer. Results were consistent in sensitivity analyses excluding patients with unpopulated costs.
Conclusions: In the US, current use of radiation therapy for bone metastases is relatively costly and the use of
multi-fraction schedules remains prevalent.
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Bone metastasis, the most common cause of cancer-
related pain, [1-3] occurs in up to 90% of patients with
advanced breast or prostate cancer [1,2,4,5]. Median
survival times for patients with breast and prostate
cancer after diagnosis of bone metastasis range from
24 to 36 months [6-8]. Care of bone metastases is
directed at decreasing skeletal complications, delaying
or relieving pain, avoiding toxicity, and maintaining
functional independence [2,9,10]. Treatment for the
care of bone metastases can include surgery, radiother-
apy, analgesics, anti-resorptive agents (e.g., denosumab,
bisphosphonates), and radiopharmaceuticals. The prevailing
treatment modality for bone metastases is radiation therapy,* Correspondence: Greg.hess@wharton.upenn.edu
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reproduction in any medium, provided the orwhich is recommended by the National Comprehensive
Cancer Network (NCCN) clinical oncology practice guide-
lines for use after or in conjunction with denosumab or
bisphosphonates in treatment of patients with breast or
prostate cancer [11,12]. Radiation therapy has been demon-
strated to be effective in pain relief and in reducing patho-
logical fractures and spinal cord compression, which may
lead to functional improvements [2,13].
Radiation treatment to bone in patients with bone
metastases contributes significantly to the overall burden
of cancer therapy [14,15] and the socioeconomic impact
is expected to increase with the aging of the populations
of developed countries [16]. Of note, approximately half
of the Medicare costs for patients with cancer are in-
curred during the last 60 days of life [15]. While it is one
of the most common treatment modalities, relatively
little is known about the economic burden of palliative
radiation therapy for bone metastases. Certain economicd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Hess et al. Radiation Oncology 2012, 7:168 Page 2 of 7
http://www.ro-journal.com/content/7/1/168modeling studies suggest that single-fraction radiation
therapy is more cost effective than pain medication,
chemotherapy, and multifraction radiation therapy [17-20].
However, these studies primarily used data from clinical
trials or the medical literature with estimated charges
and costs based on the literature, expert opinion, or pa-
tient surveys; as estimates, their results may not reliably
reflect the actual cost of radiation therapy as used in clin-
ical practice. The intent of the study reported herein was
to estimate and establish, based on current clinical prac-
tice data, the actual costs (paid amounts, rather than
charged or billed) of palliative radiation episodes of
care (REOCs) for bone metastases secondary to breast or
prostate cancer. Total radiation costs, radiation direct
costs, and the costs of radiation-related visits and proce-
dures associated with the REOC are reported.
Materials and methods
Design and setting
This retrospective, observational study was conducted
utilizing data available from a total of 98 radiation treat-
ment centers in 16 states in the United States; 96%
freestanding and 4% hospital-based. These centers provide
a range of radiation therapy services and also provide global
billing, which includes professional and technical charges
and paid amounts within a single billing process. Data were
extracted from claims-linked electronic medical records
(EMR) from the radiation treatment centers. Each center
utilizes the same EMR/billing software with a copy of the
data maintained at a central data repository, which enabled
the study. Data were de-identified and certified as being
compliant with the Health Insurance Portability and
Accountability Act (HIPAA).
Sample
Records from patients with a primary neoplasm of
breast or prostate cancer (identified by their respective
International Classification of Diseases, 9th revision
[ICD-9] codes) and a secondary neoplasm of bone me-
tastases (ICD-9, code 198.5) were analyzed. Selection
criteria for qualifying patients included the following:
1. A tumor type of interest (breast or prostate)
2. Radiation center visit date between 7/1/2008 and
12/31/2009
3. Known age and gender
4. A secondary neoplasm of bone metastases
5. At least one cost (paid) record with a monetary value
greater than zero dollars
6. ≥2 radiation visits on or after the bone metastases
diagnosis date during the study period
7. Radiation therapy to ≥1 bone site (spine, hip, femur,
skull, humerus, pelvis, shoulder, clavicle, or other
specified osseous site)8. Patients with ≥1 completed REOC as evidenced by a
>30-day gap in radiation therapy
9. Patients with <16 fractions during any REOC
(i.e. exclusion of regimens that likely reflected
miscoding and/or radiation to the soft tissues)
A REOC was defined as the first recorded visit to the
radiation center, the index date, through the last visit to
the center for that episode; the last visit was identified
by a gap of >30 days for any visit or procedure, or
recorded death (Figure 1). The 30 day duration of a gap
was chosen based on analyses of the data showing that
>96% of the qualifying study patients had less than a
30-day gap between visits.
Statistical analysis
The REOC was the unit of analysis for the outcomes of
interest. Patients could be followed across multiple
qualifying REOCs and could contribute ≥1 REOC to the
analysis. Outcomes of interest included radiation therapy
exposure, healthcare resources utilized, and the asso-
ciated paid amounts. Radiation therapy exposure was
quantified as the total dose (Gy) (i.e., the sum of all
doses received during a REOC); mean dose was assessed
by treatment, by patient, and by fraction (defined as a
unique radiation treatment); total fractions; mean and
median fractions; frequency of treatments (i.e., more
often than daily, less often than daily, or daily); count of
treatments by site radiated; and REOC duration. Health-
care resources utilized during the REOC were assessed
as visits (including consultation, simulation, treatment
planning, and treatment), procedures, and all other
healthcare resources associated with radiation therapy
for metastatic bone lesions. A visit was defined as a
unique treatment or consultation. Patients could have
≥1 visit in a day. The associated paid amounts were the
monetary payments recorded from the patient and/or a
third-party payer in the qualifying records.
Radiation therapy exposure characteristics, healthcare
resources utilized, and paid amounts as well as demo-
graphics and clinical characteristics of the sample were
summarized with descriptive statistics by tumor type
(i.e., metastatic breast or prostate cancer). For analyses
of costs, records were excluded if they had any un-
populated or absent costs in the main data analysis
which most likely represented missing values or capi-
tated amounts. To estimate the confidence interval for
the means, a bootstrap analysis of costs utilizing 1000
replications was performed. Furthermore, to determine
how unpopulated payment records could affect the
results, a sensitivity analysis was conducted in which





Start Date     End Date
7/1/08    Day 20  Day 25  Day 28
Gap of >30 days
• A visit to ≥ 1 of the radiation centers
• Radiation therapy to ≥ 1 bone site
• ≥ 1 completed REOC as evidenced by a >30-day gap in radiation therapy
• ≥ 30 days from last REOC end date to end of study period
Start Date     End Date
Day 61 to day 78
2nd REOC
12/31/09
Figure 1 Determining a Radiation Episode of Care (REOC).
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Demographics
Ninety-six percent of patients with breast or prostate
cancer in the study were treated at a free standing site
and four percent at a hospital-based site.
The number of patients in the main analysis was 207
for the breast cancer stratum and 213 for the prostate
cancer stratum. Table 1 shows demographics by cancer
stratum for the main analysis. Overall, the majority of
patients were ≥65 years old and had Medicare and/or
commercial insurance.Radiation therapy exposure
Table 1 contains the summary statistics of palliative radi-
ation therapy exposure for the treatment of metastatic
bone lesions in the main analysis. The total number of
REOCs was 220 for the 207 breast cancer patients and
233 for the 213 prostate cancer patients. The mean dur-
ation of radiation therapy during a REOC was 30 days.
Independent of cancer type, the majority of patients
received at least 10 fractions across REOCs. The most
common site radiated was the spine, which received the
greatest number of fractions across REOCs for both
breast and prostate cancer.
Healthcare resource utilization and costs
Table 2 shows summary statistics on healthcare resource
utilization in the main analysis. The mean number of vis-
its by REOC was 13, which was the same for both breast
and prostate cancer patients. For breast and prostate can-
cer respectively, 72.9% and 71.7% of REOC visits involved
radiation treatment, with the remainder reflecting visits
for radiation-related procedures. Radiation treatment wasdefined as the actual delivery of radiotherapy, as well as
the most commonly observed, associated procedures on
the same visit, patient record: medical radiation physics
consultation, computed tomography guidance for place-
ment, and radiation calculations. Radiation-related proce-
dures were all other procedures including: treatment
devices, design and construction, complex (CPT/HCPCS
code 77334); therapeutic radiology simulation-aided field
setting, 3-dimensional (CPT/HCPCS code 77295); thera-
peutic radiology simulation-aided field setting, simple
(CPT/HCPCS code 77280); and special dosimetry, when
prescribed by the treating physician (CPT/HCPCS code
77331).
Figure 2 shows summary statistics on healthcare costs
for the main or primary analysis (which excluded
records with unpopulated costs i.e. absent value, null or
zero) and Table 3 shows the results for the bootstrap
analysis of these costs. The numbers of patients included
in the main analysis were 207 for breast cancer and 213
for prostate cancer. The numbers of patients included in
the sensitivity analysis were 91 for breast cancer and 89
for prostate cancer. In the main analysis, mean total ra-
diation costs per REOC (i.e., direct radiation cost + cost
of radiation-related procedures and visits) were $7457
for breast cancer patients and $7553 for prostate cancer
patients. The corresponding numbers for the sensitivity
analysis were $7457 for breast cancer and $6936 for
prostate cancer. Mean and median total radiation costs
per REOC were generally similar between breast cancer
patients and prostate cancer patients (Figure 2). Within
the main analysis, the median costs were $6097 for
patients with breast cancer and $5634 for patients with
prostate cancer. While in the sensitivity analysis, median
costs were $6332 for patients with breast cancer and
Table 1 Baseline clinical characteristics and radiation
exposure (main analysis)
Breast cancer Prostate cancer
Patients with radiation to the bone, n 207 213
Demographics
Mean age, years (SD) 65 (12.5) 74 (8.4)
Age, n (%)
<65 years 93 (44.9) 31 (14.6)
≥65 years 114 (55.1) 182 (85.4)
Female, n (%) 202 (97.6) n/a
Payor,* n (%)
Medicare 103 (49.8) 133 (62.4)
Commercial 94 (45.4) 64 (30.0)
Medicaid 7 (3.4) 3 (1.4)
Other 3 (1.4) 13 (6.1)
Radiation profile
Total REOCs, n 220 233
Length of treatment, days
Mean (SD) 30 (16.0) 30 (16.7)
Median 26 26
Dose, cGy
Mean by episode 3207 3301
Mean per patient 3409 3611
Mean by fraction 327 337
Radiation schedule by REOC, n
Daily 201 203
Greater than daily 7 13
Less than daily** 0 0
Site radiated by REOC*** n (%)
Femur 14 (6.8) 28 (13.1)
Hip 45 (21.7) 40 (18.8)
Humerus 3 (1.4) 9 (4.2)
Pelvis 20 (9.7) 34 (16.0)
Rib 12 (5.8) 12 (5.6)
Sacrum 21 (10.1) 17 (8.0)
Skull 9 (4.3) 10 (4.7)
Spine 97 (46.9) 95 (44.6)
Other bone sites 28 (13.5) 27 (12.7)
Total fractions 2173 2344
Fractions by REOC




4 to 5 21 23
10 35 43
15 47 47
Table 1 Baseline clinical characteristics and radiation
exposure (main analysis) (Continued)
Other 102 96









Other bone site 8.8 10.4
*A patient could have multiple payor coverage for the same procedure.
** Every other day.
*** A patient could be counted multiple times with radiation to the same site
or to multiple sites.
† Fractionation schedule is the count of unique patients by the range of total
number of fractions across REOCs.
‡ Fractions by site are a sum of all fractions received across REOCs stratified by
bone site.
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results did not materially differ between the main ana-
lysis and the sensitivity analysis.Discussion
Increasing limitations on healthcare resources and the
recognition that treatment of bone metastases contri-
butes significantly to the socioeconomic burden of can-
cer have led to calls to evaluate and better understand
costs associated with treatment [14-16]. This study
quantified the recorded, actual, and paid costs of pallia-
tive radiation therapy for bone metastases secondary to
breast or prostate cancer. Results from the analysis dem-
onstrate that the total cost of radiation therapy for bone
metastases was substantial. Mean total radiation costs
(i.e., direct radiation cost + cost of radiation-related pro-
cedures and visits excluding actual radiation) per REOC
were $7457 for breast cancer patients and $7553
for prostate cancer patients. Radiation direct costs
accounted for the majority of total radiation costs. Total
radiation costs did not differ materially between breast
cancer and prostate cancer. Likewise, total radiation
costs did not differ materially as a function of how un-
populated payment records were accounted for (i.e.,
records with unpopulated costs excluded from the
main analysis; patients with unpopulated cost records
excluded from the sensitivity analysis).
Palliative radiation practices including length of treat-
ment, dose, radiation schedule, fractions by REOC, and
frequency of fractions, appear to be similar for the
treatment of patients with breast or prostate cancer.
Table 2 Healthcare resource utilization (Main Analysis)




Mean (SD) number of visits 13 (5.8) 13 (5.8)
Median number of visits 13 14
% visits with radiation 72.9 71.7
Procedures
Bone sites radiated by REOC
Patient count 207 213
Total 4607 4739
Mean (SD) 20.9 (12) 20.3 (12)
Median (range) 19 (1–49) 17 (1–58)
Radiation-related procedures†
Patient count 203 212
Total procedures 1843 1984
Mean (SD) procedures 8.4 (3) 8.5 (4)
Median (range) procedures 8 (1–23) 8 (1–32)
Radiation+radiation-related procedures
Patient count 207 213
Total procedures 6450 6723
Mean (SD) procedures 29.3 (13) 28.9 (13)
Median (range) procedures 28 (1–66) 26 (1–76)
* A visit was a unique treatment or consultation. A patient could have multiple
visits in a day.
Total resources used from the time of initial bone treatment through the end
of the study period.
† Radiation treatment included the actual delivery of radiotherapy, as well as
the most commonly observed, associated procedures on the same visit,
patient record: medical radiation physics consultation, computed tomography
guidance for placement, and radiation calculations. Radiation-related
procedures were all other procedures including: treatment devices, design and
construction, complex (CPT/HCPCS code 77334); therapeutic radiology
simulation-aided field setting, 3-dimensional (CPT/HCPCS code 77295);
therapeutic radiology simulation-aided field setting, simple (CPT/HCPCS code
77280); and special dosimetry, when prescribed by the treating physician
(CPT/HCPCS code 77331).
Figure 2 Main analysis of healthcare costs ($) per REOC.
*Radiation-related procedures were visits and procedures at
radiation center excluding actual administration of radiation.
Radiation-related procedures included intensity-modulated
treatment delivery, single or multiple fields/arcs, via narrow spatially
and temporally modulated beams, binary, dynamic multileaf
collimator, per treatment session (Current Procedural
Terminology/Healthcare Common Procedure Coding System
[CPT/HCPCS] code 77418); treatment devices, design and
construction, complex (CPT/HCPCS code 77334); therapeutic
radiology simulation-aided field setting, 3-dimensional (CPT/HCPCS
code 77295); therapeutic radiology simulation-aided field setting,
simple (CPT/HCPCS code 77280); special dosimetry, only when
prescribed by the treating physician (CPT/HCPCS code 77331).
†Excluded records with unpopulated costs.
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also similar for the treatment of patients with breast or
prostate cancer. The most commonly irradiated bone
sites for both cancer types were the spine and the hip,
and the least common was the humerus; most likely
reflecting the variations in incidence, surrounding
normal-tissue tolerance, extent of metastatic lesion(s),
and other factors.
In addition to quantifying the costs of radiation therapy
as used in current clinical practice, the results of this
study sheds light on US practice patterns of radiation to
bone in patients with bone metastases. Current guide-
lines indicate that radiotherapy is a successful and effi-
cient method by which to palliate pain and/or prevent
the morbidity of bone metastases [21]. For the majorityof patients with breast or prostate cancer, the median
number of fractions per REOC was 10; a result reflecting
common use of multifraction therapy. Clinical evidence,
including that from three large, randomized trials of
single-fraction therapy (8 Gy) vs. multifraction therapy
(20 to 30 Gy), demonstrates that single-fraction therapy
may be as effective as multifraction therapy for the
treatment of bone metastases [21-24]. Although single-
fraction therapy may be as clinically effective, more
convenient for the patient, and less expensive than mul-
tifraction therapy, single-fraction therapy has not currently
Table 3 Bootstrap estimates of standard errors (SEs) and
95% confidence intervals for costs ($)
Observed Bootstrap 95% Confidence
interval
mean, $ SE Lower Upper
Breast cancer
Radiation direct costs 4812 298 4229 5395
Radiation-related costs* 2645 124 2402 2889
Total radiation costs 7457 383 6707 8208
Prostate cancer
Radiation direct costs 4950 325 4314 5587
Radiation-related costs* 2603 118 2372 2834
Total radiation costs 7553 410 6749 8357
* Visits and procedures at radiation center excluding actual administration of
radiation.
Hess et al. Radiation Oncology 2012, 7:168 Page 6 of 7
http://www.ro-journal.com/content/7/1/168been accepted as standard practice in the US [25,26]. A
contributing factor may be the durability of the pain re-
sponse as multifraction regimens (10 fractions vs. 1 frac-
tion) have been associated with less re-treatment. This
point is supported by the median and mean numbers of
fractions observed per REOC for patients with breast or
prostate cancer in the current study, which indicates that
the use of multi-fraction schedules in the management of
patients with advanced breast or prostate cancer and bone
metastases is common, and is likely associated with a sub-
stantial patient burden.
Strengths of this study include its geographical diver-
sity (data from 98 radiation cancer treatment centers in
16 US states), reflection of recent practice patterns
(study period from 1 July 2008 to 31 December 2009),
and “real-world” reflections (data based on electronic
medical records from freestanding and hospital-based
cancer treatment centers). However, the results reflect
centers in 16 states and it is unknown if other centers,
particularly in the other 34 states, would present similar
findings. Limitations, typical of retrospective, claims-
based studies, include the potential for coding errors
and underreported or missing information on historical
radiation treatment. In addition, the limitation of incom-
plete patient records, a typical shortcoming of claims-
based studies, was addressed in the current study by
undertaking a sensitivity analysis where patients were
excluded if they had any unpopulated or absent cost
records. The results on healthcare resource use and the
cost data were similar and followed a consistent pattern
across analysis methods, suggesting that the occurrence
of incomplete payment records did not systematically
affect the results. The results are specific to patients with
bone metastases treated with radiation therapy, and the
cost for those not treated with radiation was not studied.
Lastly, it is important to note that these results describe
an ‘average’ patient, and we know as clinicians andresearchers that patients are individuals that follow a
broad range of patterns.
Future research to examine concurrence or variations of
these findings within other states will be beneficial, as well
as exploring additional areas such as the correlation of the
number of radiation procedures by site irradiated with
increased cost, the relative costs of various radiation regi-
mens and fractionation schedules, the cost-effectiveness of
radiation therapy compared to alternative therapies for
bone metastases, costs incurred without radiation therapy
e.g. cord compression, and cost differences between pri-
vate payers, Medicare and Medicaid, and/or academic and
non-academic facilities.
Conclusions
The results of this study show that in the United States,
palliative radiation treatment of bone metastases in
patients with breast or prostate cancer represents a sig-
nificant cost burden. Furthermore, the study provides a
foundation for evaluating the relative costs of current
and investigational therapies for the treatment of bone
metastases.
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